The bispecific antibody is used to treat patients with relapsed or refractory multiple myeloma (R/R MM) who have achieved and maintained a complete response for at least 6 months; this approval allows a dosing frequency of 1.5 mg/kg every 2 weeks.
Expert panelists provide an overview of adverse events associated with bispecific antibodies for the treatment of multiple myeloma along with best practices for monitoring and treating adverse events.
Medical experts dissect critical strategies for monitoring for potential adverse events with bispecific antibodies in a comprehensive panel discussion.